Trial Profile
An Open-label, Non-randomized, Multicenter, Two Stage Designed Phase II Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AXIPAN
- 05 Oct 2018 Results published in the BJU International.
- 24 Jul 2017 Status changed from active, no longer recruiting to completed.
- 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association